A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data
Tania Nikolcheva, Gennaro Pagano, Nathalie Pross et al. · Parkinsonism & Related Disorders · 2024
INTRODUCTION: Prasinezumab was shown to potentially delay motor progression in individuals with early-stage Parkinson's disease (PD) who were either treatment-naïve or on monoamine oxidase type B inhibitor (MAO-Bi) therapy in the PASADENA study. We report the rationale, design, and baseline patient characteristics of the PADOVA study, designed to evaluate prasinezumab in an early-stage PD population receiving standard-of-care (SOC) symptomatic medications. METHODS: PADOVA (NCT04777331) is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, in which individuals with early-stage PD on SOC stable symptomatic monotherapy (levodopa or MAO-Bi) receive intravenous prasinezumab 1500 mg every 4 weeks. The primary endpoint is time to confirmed motor progression, defined as ≥5 points increase from baseline on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III in practically defined OFF-medication state. RESULTS: 586 participants were enrolled between May 5th, 2021 and March 22nd, 2023. At baseline, 74.2 % and 25.8 % of participants were receiving levodopa and MAO-Bi, respectively. Mean age was 64.2 years and 63.5 % were male. Mean time from diagnosis was 18.6 months, 85 % of participants were in Hoehn & Yahr (H&Y) Stage 2, and mean MDS-UPDRS Part III score was 24.5. Compared with the PASADENA population, PADOVA participants were older (∼5 years), with longer disease duration (∼8 months), and slightly more advanced based on H&Y stage (10 % more in Stage 2) and MDS-UPDRS Part III (∼3 points more). CONCLUSIONS: PADOVA has successfully recruited an early-stage PD population to test the effect of prasinezumab when added to background SOC.
Cited by 20 works. doi:10.1016/j.parkreldis.2024.107257
Authors
- Tania Nikolcheva
- Gennaro Pagano
- Nathalie Pross
- Tanya Simuni
- KENNETH L. MAREK
- Ronald B. Postuma
- Nicola Pavese
- Fabrizio Stocchi
- Klaus Seppi
- Annabelle Monnet
- Nima Shariati
- Benedicte Ricci
- Loes C.A. Rutten‐Jacobs
- Gesine Respondek
- Thomas Kustermann
- Kirsten I. Taylor
- Dylan Trundell
- Paulo Fontoura
- Rachelle Smith Doody
- Hanno Svoboda
References
- MDS clinical diagnostic criteria for Parkinson's disease
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- Optimally weighted, fixed sequence and gatekeeper multiple testing procedures
- Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
- Trial of Prasinezumab in Early-Stage Parkinson’s Disease
- Minimal clinically important difference on the Motor Examination part of MDS-UPDRS
- Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease
- First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers
- Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson’s disease